Bringing Mirvetuximab Soravtansine, an FR-alpha Directed ADC, to Patients with Ovarian Cancer

Time: 9:00 am
day: Day One


  • Discussing efficacy and safety of MIRV in FR-alpha high, platinum resistant ovarian cancer
  • Outlining the evolution of the companion diagnostics and impacts on trials
  • Sharing information about on-going trials and next steps